GlassScriptPhysician profile
Jacob Bartlett
NPI 1487325569
$6,575.66
in general payments reported to CMS, 2019-2025
25 companies · $3,328 in 2025
The $3,328 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $331 · 2024: $2,918 · 2025: $3,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803 · Consulting Fee: $2,498 · Travel and Lodging: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.29 |
| Consulting Fee | $2,497.50 |
| Travel and Lodging | $1,169.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $4,046.53 | 2024-2025 | Carvykti |
| Janssen Biotech, INC. | $283.21 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Incyte Corporation | $272.36 | 2024-2025 | Jakafi, Niktimvo, Niktimvo |
| Jazz Pharmaceuticals INC. | $225.19 | 2023 | |
| Celgene Corporation | $216.62 | 2024-2025 | Pomalyst, Reblozyl, Breyanzi |
| Janssen Scientific Affairs, LLC | $194.65 | 2024-2025 | Tecvayli, Talvey, Carvykti |
| Secura Bio, INC. | $170.01 | 2025 | Copiktra |
| Genmab U.S., INC. | $157.21 | 2024 | Epkinly |
| Astellas Pharma US INC | $145.69 | 2024 | Cresemba |
| Kite Pharma, INC. | $143.31 | 2025 | Yescarta |
| Servier Pharmaceuticals LLC | $124.66 | 2025 | |
| Rigel Pharmaceuticals, INC. | $114.65 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $92.29 | 2024-2025 | Venclexta, Polivy, Columvi |
| Syndax Pharmaceuticals, INC. | $43.14 | 2025 | |
| Abbvie INC. | $27.75 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $24.67 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $24.52 | 2025 | |
| Merck Sharp & Dohme LLC | $24.47 | 2024 | Prevymis, Zerbaxa, Dificid |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2024 | |
| Daiichi Sankyo INC. | $21.62 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $20.05 | 2025 | Lynozyfic |
| Paratek Pharmaceuticals, INC. | $19.81 | 2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $18.73 | 2024 | Xerava |
| Novartis Pharmaceuticals Corporation | $18.49 | 2024 | |
| Amgen INC. | $18.43 | 2024 | Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bartlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.